Neoprobe CEO Mark Pykett said the company could announce the new-drug application filing for its radiopharmaceutical Lymphossek within the next 30 days. "We are finalizing the integrated NDA document and completing the final quality checks of our electronic submission and look forward to announcing the submission within the next month," Pykett said.

Full Story:

Related Summaries